HCM vs. ASND, MRNA, BBIO, BPMC, VRNA, ROIV, ELAN, RVMD, LEGN, and GRFS
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.
HUTCHMED vs. Its Competitors
Ascendis Pharma A/S (NASDAQ:ASND) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.
8.8% of HUTCHMED shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Ascendis Pharma A/S currently has a consensus target price of $220.67, suggesting a potential upside of 25.39%. HUTCHMED has a consensus target price of $19.00, suggesting a potential upside of 23.22%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than HUTCHMED.
HUTCHMED has higher revenue and earnings than Ascendis Pharma A/S.
Ascendis Pharma A/S has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
In the previous week, Ascendis Pharma A/S had 7 more articles in the media than HUTCHMED. MarketBeat recorded 8 mentions for Ascendis Pharma A/S and 1 mentions for HUTCHMED. Ascendis Pharma A/S's average media sentiment score of 0.55 beat HUTCHMED's score of 0.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.
HUTCHMED has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -93.22%.
Summary
Ascendis Pharma A/S beats HUTCHMED on 7 of the 13 factors compared between the two stocks.
Get HUTCHMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
This page (NASDAQ:HCM) was last updated on 7/8/2025 by MarketBeat.com Staff
